Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
05/04/2023 - 04:01 PM
WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 11, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023, and recent business highlights.
Listeners can register for the webcast via this link . Analysts wishing to participate in the question and answer session should use this link . A replay of the webcast will be available in the investor section of the company’s website approximately two hours after the end of the call. Those who plan on participating are advised to join 15 minutes prior to the start time.
About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Media Contact: Kate Burdick, Evoke Canale 860-462-1569 kate.burdick@evokegroup.com
Investor Contact: Chris Brinzey, ICR Westwicke 339-970-2843 chris.brinzey@westwicke.com
IVVD Rankings
#4901 Ranked by Stock Gains
IVVD Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
About IVVD
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.